Filing Analysis
Oncotelic Therapeutics entered into a Securities Purchase Agreement with Pacific Pier Capital II, LP involving the issuance of a $178,410 convertible promissory note and 500,000 commitment shares. The financing includes high interest rates and a floating conversion price that could lead to significant dilution.
🚩 Red Flags
- Death Spiral Feature: The conversion price includes a floating component (85% of the lowest traded price), which typically leads to massive dilution in micro-cap companies.
- High Cost of Capital: 12% interest rate plus a 12% OID is extremely expensive for a company seeking small amounts of capital ($178k).
- Low Valuation/Price Floor: The $0.06 fixed conversion price suggests the company's equity value is perceived as very low.
- Small Funding Amount: A principal amount of only $178,410 is extremely low for a public company, suggesting potential liquidity or cash flow distress.
📋 Key Facts
- Date of agreement: August 3, 2026
- Principal amount of Note 2: $178,410
- Original Issue Discount (OID): 12%
- Interest rate: 12% per annum; Default interest: 16%
- Maturity: One-year anniversary or upon Event of Default/prepayment
- Conversion Price: Fixed at $0.06 per share or 85% of the lowest traded price over the 10 trading days prior to conversion
- Additional issuance: 500,000 shares of Common Stock issued as 'Commitment Shares'
Oncotelic Therapeutics, Inc. announced the board's approval of 17,796 Restricted Stock Units (RSUs) granted to directors, officers, and key employees. These RSUs are tied to a specific performance milestone: the company must uplist its common stock onto a national exchange by June 30, 2027.
🚩 Red Flags
- Performance-based vesting tied to a national exchange uplisting suggests the company is currently trading on an over-the-counter (OTC) market and lacks liquidity/status.
- The structure of the RSUs (converting to Preferred Stock which then converts into 1,000 Common Shares) creates significant potential dilution for existing common shareholders upon conversion.
📋 Key Facts
- Total of 17,796 RSUs granted to directors, officers, and employees/advisors.
- RSUs vest only if the company's common stock is uplisted onto a national stock exchange on or before June 30, 2027 (or an extension).
- Vesting requires recipients to remain in service for six months following the uplisting.
- Each RSU settles into one share of Series A Convertible Preferred Stock, which is convertible into 1,000 shares of Common Stock.
- Issuance relies on Section 4(a)(2) exemption from registration requirements.
Oncotelic Therapeutics, Inc. filed an 8-K to announce that it presented a corporate presentation to its employees, directors, officers, and advisors on July 13, 2026.
📋 Key Facts
- The company delivered a 'Corporate Presentation' to internal stakeholders (employees, directors, officers) and advisors on July 13, 2026.
- The presentation is attached as Exhibit 99.1.
- The information provided under Item 8.01 is furnished but not considered 'filed' for purposes of Section 18 of the Exchange Act.
Oncotelic Therapeutics entered into a Securities Purchase Agreement with Pacific Pier Capital II, LP involving a $178,410 convertible promissory note and 500,000 commitment shares. The deal features highly dilutive conversion terms including a floating price mechanism.
🚩 Red Flags
- Highly dilutive 'death spiral' feature: The conversion price includes a floating mechanism (85% of the lowest traded price over 10 days).
- Extremely low conversion price ($0.06) relative to typical micro-cap valuations, suggesting significant dilution.
- High interest rate (12%) and OID (12%) on a relatively small principal amount, indicating expensive capital.
- Unregistered sale of equity securities (exempt from registration under Section 4(a)(2)).
📋 Key Facts
- Entered into a Securities Purchase Agreement (SPA) with Pacific Pier Capital II, LP on June 23, 2026.
- Issued a convertible promissory note for an aggregate gross principal amount of $178,410.
- Note carries a 12% annual interest rate and a 12% original issue discount (OID).
- Conversion price is set at either $0.06 per share or 85% of the lowest traded price during the 10 trading days prior to conversion.
- Issued 500,000 shares of Common Stock as commitment shares to Pacific Pier.
- Default interest rate increases to 16% upon an Event of Default.
Oncotelic Therapeutics completed the issuance of 32 units to 21 accredited investors as part of a larger offering. The transaction involves convertible notes with highly dilutive terms and includes complex conversion rights involving its subsidiary, EdgePoint AI, Inc.
🚩 Red Flags
- Extreme dilution risk: Conversion price of $0.10 per share and warrant exercise at $0.12 suggests a highly distressed valuation.
- Complex/Opaque structure: The inclusion of conversion rights into a subsidiary (EdgePoint AI) complicates the capital structure for public shareholders.
- Debt-heavy financing: Issuance of 12% interest-bearing convertible notes indicates high cost of capital, typical of companies with limited traditional financing options.
📋 Key Facts
- Completed issuance of 32 Units on December 23, 2025.
- Each Unit consists of one $25,000 Note bearing 12% annual interest due in 2 years.
- Notes are convertible into up to 250,000 shares of Oncotelic Common Stock at $0.10 per share or 25,000 shares of EdgePoint AI, Inc. common stock at $1.00 per share.
- Each Unit includes 250,000 warrants to purchase one share of Oncotelic Common Stock at $0.12 per share.
- The offering is being conducted via Rule 506 of Regulation D (unregistered).
- Includes a Registration Rights Agreement for shares issued in the financing.
Oncotelic Therapeutics announced the launch of PDAOAI, a proprietary evidence-interrogation platform for biomedical data analysis. The company is also providing researchers access to a TGF-β literature corpus via a dedicated Discord channel.
🚩 Red Flags
- Forward-looking statements mention highly speculative/unrelated activities such as 'the launch of a company with a DAO infrastructure' and the registration of 'tokens' (Pet2DAO) which may be considered securities.
📋 Key Facts
- Launched PDAOAI, an evidence-interrogation platform designed to extract signals from complex biomedical datasets without training bespoke LLMs on proprietary data.
- Providing open access to a TGF-β literature corpus containing over 125,000 PubMed abstracts via Discord.
- The filing includes forward-looking statements regarding various ventures including a JV IPO, nanoparticle platform success, and potential token launches (Pet2DAO).
Oncotelic Therapeutics has commenced a unit offering of up to 500 units, with 11 units already subscribed. The offering consists of convertible notes and warrants featuring extremely low conversion prices relative to the exercise prices.
🚩 Red Flags
- Extreme dilution risk due to very low conversion prices ($0.10) compared to warrant exercise prices ($0.12).
- Highly complex structure involving a minority-owned subsidiary (EdgePoint AI, Inc.) and dual-stock conversion options.
- Significant potential for 'death spiral' mechanics if the stock price fluctuates near the $0.10-$0.12 range.
- The offering is being used to settle/refinance prior 2023 debt (PPM Notes), suggesting ongoing liquidity pressure.
📋 Key Facts
- Completed subscription for 11 Units on December 4, 2025.
- Total offering size: up to 500 Units.
- Each Unit contains one $25,000 Note with a 12% annual interest rate due in 2 years.
- Notes are convertible into Oncotelic Common Stock at $0.10 per share or EdgePoint AI, Inc. stock at $1.00 per share.
- Warrants allow purchase of Oncotelic Common Stock at $0.12 per share or EdgePoint warrants at $1.25 per share.
- Existing 2023 PPM Note holders can exchange old notes for these new Units; existing Edgepoint shareholders can convert to Oncotelic stock at a rate of 1:10 ($0.10/share).
- The offering is being conducted under Rule 506 of Regulation D (unregistered).
Oncotelic Therapeutics announced that its CEO, Dr. Vuong Trieu, presented a corporate presentation at the LD Micro conference in San Diego on October 21, 2025.
🚩 Red Flags
- The forward-looking statements mention highly speculative activities including 'the success of the launch of a company with a DAO infrastructure', 'plans surrounding the pet and animal health', and 'ability to register tokens... as registrable securities'.
📋 Key Facts
- CEO Dr. Vuong Trieu presented at LD Micro in San Diego, CA.
- The presentation included forward-looking statements regarding clinical development, regulatory approvals, and a nanoparticle platform.
- Filing date: October 22, 2025; Event date: October 21, 2025.
Oncotelic Therapeutics entered into independent contractor agreements with Jefferson Capital Ventures, LLC and Valor Nation, Inc. for strategic advisory services. The compensation includes significant equity issuances tied to specific corporate milestones.
🚩 Red Flags
- Significant dilution risk: Over 24 million shares are being allocated to consultants via equity-based compensation.
- Milestone-based equity triggers (market cap and uplisting) can create aggressive incentives for management/consultants to influence stock price or reporting.
- Potential related-party transaction concerns regarding the nature of 'advisory services' provided by Jefferson and Valor.
📋 Key Facts
- Entered into ICAs with Jefferson Capital Ventures, LLC and Valor Nation, Inc. on August 6, 2025.
- Jefferson to receive $20,000/month in cash plus up to 20,320,930 forfeitable restricted stock awards (RSAs).
- Valor to receive 4,064,586 shares of Common Stock.
- Jefferson's RSAs are contingent upon three milestones: market cap >$100M, $10M increase in shareholder equity, and successful uplisting to a U.S. national exchange (Nasdaq/NYSE American).
- Valor has already earned their RSAs as of the signing date.
- Issuance is exempt from registration under Section 4(a)(2) of the Securities Act.
Oncotelic Therapeutics entered into multiple debt and equity agreements with Mast Hill Fund, LP, including a $560,000 convertible promissory note and an equity purchase agreement (EPA) allowing for up to $25 million in staged stock purchases. The transactions involve significant dilution through warrants and convertible notes at prices potentially below market value.
🚩 Red Flags
- Significant potential dilution from multiple tranches of warrants (5.35 million total) and convertible notes.
- The use of an Equity Purchase Agreement (EPA/'Death Spiral' style mechanism) where the company can force purchases at a discount to market price (97%).
- High interest rate (10%) combined with a 10% original issue discount on debt.
- Multiple material agreements filed simultaneously in one 8-K, indicating complex and urgent financing needs.
📋 Key Facts
- Entered into 2025 Mast Hill Purchase Agreement on July 31, 2025, involving a $560,000 convertible promissory note.
- The note carries a 10% interest rate and an original issue discount (OID) of 10%.
- Note allows for voluntary conversion at a fixed price of $0.07 per share.
- Issued 2,000,000 warrants to Mast Hill with an exercise price of $0.15.
- Entered into an Equity Purchase Agreement (EPA) on August 1, 2025, for up to $25 million in common stock via 'Put Notices'.
- The EPA includes a warrant issuance of 3,350,000 shares of Common Stock.
- Mast Hill has the right to purchase stock at 97% of the Market Price or 102% of the Market Alternative Price.
Oncotelic Therapeutics announced a presentation by CEO Dr. Vuong Trieu at the 5th Symposium on World Cancer Research (SWCR) 2025 and reported successful Phase 1 clinical trial results for OT-101 combined with recombinant IL-2.
📋 Key Facts
- CEO Dr. Vuong Trieu presented research on Transforming Growth Factor Beta 2 at SWCR 2025 on March 23, 2025.
- The company announced successful results from a Phase 1 clinical trial involving OT-101 and recombinant IL-2 (aldesleukin) on March 25, 2025.
- Presentation materials are included as Exhibit 99.1.
Oncotelic Therapeutics has extended the deadline for a potential reverse merger with Mosaic ImmunoEngineering, Inc. to June 30, 2025. This follows multiple previous extensions of a binding term sheet originally entered into in April 2024.
🚩 Red Flags
- Repeated delays/extensions of a proposed transaction suggest uncertainty in closing the deal.
- Management disclaimer stating there is no guarantee a definitive agreement will ever be reached.
- The nature of 'reverse mergers' often involves companies seeking to bypass traditional IPO routes, which can sometimes signal liquidity or listing challenges.
📋 Key Facts
- The Company and Mosaic ImmunoEngineering agreed on December 31, 2024, to extend the deadline for their 'Proposed Transaction' (a possible reverse merger).
- The new deadline for completing the transaction is no later than June 30, 2025.
- Previous extensions were reported in the Q2 2024 10-Q filing, which moved the date to December 31, 2024.
- The company explicitly states there are 'no guarantees' that a definitive agreement will be entered into.
Oncotelic Therapeutics has entered into a binding term sheet with Mosaic ImmunoEngineering for the licensing of CA4P. The deal includes potential equity and cash payments totaling up to $45 million, but contains highly unusual clauses regarding loans to the partner and a potential reverse merger.
🚩 Red Flags
- Reverse merger contingency: The agreement includes a clause where the transaction converts to a reverse merger if Oncotelic fails to help Mosaic raise $2M.
- Unusual lending activity: Oncotelic is providing loans to its partner (Mosaic) to cover their operational/audit costs.
- Complex dependency: Oncotelic's ability to secure its own deal is tied to the successful fundraising of a third party (Mosaic).
📋 Key Facts
- Entered into a binding term sheet with Mosaic ImmunoEngineering on April 26, 2024.
- Mosaic to pay Oncotelic $15 million in shares upon closing of definitive agreement for CA4P indications.
- Potential for an additional $15 million in cash and $15 million in Mosaic shares based on milestones.
- Oncotelic will loan Mosaic funds to cover audit/operational costs until June 1, 2024.
- Oncotelic is obligated to assist Mosaic in raising at least $2 million; failure to do so triggers a potential reverse acquisition/merger clause.
Oncotelic Therapeutics completed the fourth tranche of a financing round, issuing 12 units consisting of convertible promissory notes and warrants to accredited investors. This tranche involved converting $0.5 million of existing debt into new equity-linked instruments.
🚩 Red Flags
- Highly dilutive financing: Conversion price ($0.10) and warrant exercise price ($0.12) are extremely low, suggesting significant dilution for existing shareholders.
- Death Spiral potential: The use of convertible notes with fixed conversion prices in a micro-cap context often leads to rapid share issuance upon conversion.
- Continued reliance on debt/equity conversions: This is the fourth tranche of an ongoing financing cycle initiated in July 2023, indicating persistent capital needs.
📋 Key Facts
- Completed issuance of 12 Units on January 29, 2024.
- Each Unit contains one $25,000 convertible promissory note (totaling $300,000 in new notes).
- Notes are convertible into common stock at a price of $0.10 per share (up to 250,000 shares per note).
- Each Unit includes 250,000 warrants to purchase common stock at $0.12 per share.
- The transaction involved converting $0.5 million of existing debt from four accredited investors into the current Subscription Agreements.
- Placement agent JH Darbie & Co., Inc. received $45,000 in fees and 13% of the warrants issued.